Evidence map›Paper›PMID 30674720›Full record

ReviewJCI insight2019

Integrating molecular pathogenesis and clinical translation in sepsis-induced acute respiratory distress syndrome.

Joshua A Englert, Christopher Bobba, Rebecca M Baron

Registry-linked trialAbstract readReview
In one paragraph

Review in JCI insight, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04969991 (A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Varespladib in Patients Hospitalized With Severe COVID 19 Caused by SARS-CoV-2), which is not on this map. Cited by 125 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04969991 phase2terminatednot on this mapstarted 2021, after this paper: background citation

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Varespladib in Patients Hospitalized With Severe COVID 19 Caused by SARS-CoV-2

TypeinterventionalSponsorOphirex, Inc.Ran2021 to 2022Enrolled18ConditionsCoronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2ArmsVarespladib, Placebo
3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Acquired cystic fibrosis transmembrane conductance regulator dysfunction.Pflugers Archiv : European journal of physiology · 2025
    Review
  18. Article
  19. Article
  20. Review

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Joshua A EnglertDivision of Pulmonary, Critical Care and Sleep Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Christopher BobbaDivision of Pulmonary, Critical Care and Sleep Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Rebecca M BaronDivision of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Funding

MicroRNA-181b and SepsisR01GM115605 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI BARON, REBECCA M, FEINBERG, MARK W · 2015 to 2018
$1.8M
Role of mTORC1 in ventilator induced lung injuryK08GM102695 · NIGMS · OHIO STATE UNIVERSITY · PI ENGLERT, JOSHUA A · 2013 to 2017
$998k
Dissecting the molecular mechanisms of lung injury during mechanical ventilationR56HL142767 · NHLBI · OHIO STATE UNIVERSITY · PI ENGLERT, JOSHUA A · 2018 to 2018
$583k
NHLBI NIH HHS R56 HL142767NIGMS NIH HHS K08 GM102695NIGMS NIH HHS R01 GM115605
6 · The paper itself

Abstract

Sepsis-induced acute respiratory distress syndrome (ARDS) has high morbidity and mortality and arises after lung infection or infection at extrapulmonary sites. An aberrant host response to infection leads to disruption of the pulmonary alveolar-capillary barrier, resulting in lung injury characterized by hypoxemia, inflammation, and noncardiogenic pulmonary edema. Despite increased understanding of the molecular biology underlying sepsis-induced ARDS, there are no targeted pharmacologic therapies for this devastating condition. Here, we review the molecular underpinnings of sepsis-induced ARDS with a focus on relevant clinical and translational studies that point toward novel therapeutic strategies.

Identifiers

PMID30674720
PMCPMC6413834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.